AbbVie News Center - News
WEB1 day ago · AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs. September 06, 2024.
AbbVie Submits Biologics License Application to the FDA for ...
WEB1 hour ago · AbbVie (NYSE: ABBV) today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of telisotuzumab vedotin (Teliso-V ...
AbbVie Announces Positive Topline Results from Phase 3 TEMPO …
WEB1 day ago · AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease. Tavapadon is an investigational D1 ...
AbbVie Parkinson’s drug from $8.7B Cerevel buyout scores
WEB1 day ago · That trial is testing the drug as a flexible-dose monotherapy. The pharma got its hands on tavapadon last year after buying out Cerevel Therapeutics for a whopping $8.7 billion. The other shining ...
AbbVie’s $8.7bn Parkinson’s disease drug shines in Phase III trial
WEB6 hours ago · AbbVie inherited tavapadon in August 2023 after it acquired Cerevel Therapeutics in an $8.7bn deal. The drug candidate is being evaluated in four clinical trials, dubbed TEMPO-1 to 4. These ...
AbbVie Completes Acquisition of Cerevel Therapeutics
WEBAug 1, 2024 · AbbVie Completes Acquisition of Cerevel Therapeutics. Cerevel's clinical-stage assets complement AbbVie's emerging neuroscience pipeline and leading on-market brands in psychiatry, migraine and Parkinson's disease.
AbbVie to Acquire ImmunoGen, including its Flagship Cancer ... - News
WEBNov 30, 2023 · The acquisition accelerates AbbVie's commercial and clinical presence in the solid tumor space. Additionally, ImmunoGen's follow-on pipeline of promising next-generation ADCs further complements AbbVie's ADC platform and existing programs.
AbbVie's Parkinson's Disease drug meets main goal in late-stage …
WEB1 day ago · AbbVie said on Thursday its drug met the main goal in a late-stage trial in patients with early Parkinson's disease. ... Reuters, the news and media division of Thomson Reuters, is the world’s ...
AbbVie Seeks Accelerated FDA OK of Teliso-V in Non-Small Cell …
WEB17 hours ago · AbbVie Seeks Accelerated FDA OK of Teliso-V in Non-Small Cell Lung Cancer. By Colin Kellaher. AbbVie has filed for accelerated Food and Drug Administration approval of its proposed antibody-drug ...
AbbVie to Acquire Cerevel Therapeutics in Transformative …
WEBDec 6, 2023 · AbbVie will acquire all outstanding Cerevel common stock for $45.00 per share in cash. The proposed transaction is subject to customary closing conditions, including receipt of regulatory...